Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

38.51
+0.20000.52%
Volume:1.05M
Turnover:40.59M
Market Cap:22.46B
PE:21.98
High:38.69
Open:38.31
Low:38.31
Close:38.31
52wk High:41.24
52wk Low:24.05
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.35
T/O Rate:0.28%
Dividend:0.87
Dividend Rate:2.26%
EPS(TTM):1.75
EPS(LYR):1.92
ROE:13.11%
ROA:5.22%
PB:3.50
PE(LYR):20.09

Loading ...

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Yesterday

How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal

Simply Wall St.
·
Dec 17

Royalty Pharma - Buys Low-Single Digit Royalty on Neladalkib and Zidesamtinib

THOMSON REUTERS
·
Dec 16

Royalty Pharma - Royalty Duration for Both Therapies Extends Through 2041 to 2042

THOMSON REUTERS
·
Dec 16

Royalty Pharma (RPRX): Revisiting Valuation After Fresh Analyst Upgrades and Strengthening Buy-Side Consensus

Simply Wall St.
·
Dec 15

Royalty Pharma : TD Cowen Raises Target Price to $45 From $42

THOMSON REUTERS
·
Dec 11

EVP, Investments & CLO George W. Lloyd Reports Disposal of Royalty Pharma plc Common Shares

Reuters
·
Dec 06

Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

Benzinga_recent_news
·
Dec 06

Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment

Dow Jones
·
Dec 04

Denali Therapeutics Inc - Royalty Pharma to Receive 9.25% Royalty on Worldwide Sales of Tividenofusp Alfa From Denali

THOMSON REUTERS
·
Dec 04

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Dec 04

Will Raised 2025 Guidance and CFO Share Sale Shift Royalty Pharma's (RPRX) Growth Narrative?

Simply Wall St.
·
Nov 29

Royalty Pharma CFO Terrance P. Coyne Reports Sale of Common Shares

Reuters
·
Nov 27

Royalty Pharma to Present at Citi and Evercore Healthcare Investor Conferences

Reuters
·
Nov 26

Royalty Pharma EVP George W. Lloyd Reports Sale of Common Shares

Reuters
·
Nov 22

Royalty Pharma plc Publishes Transcript of Q3 2025 Earnings Call

Reuters
·
Nov 11

A Look at Royalty Pharma’s (RPRX) Valuation Following Upgraded Guidance and Buybacks

Simply Wall St.
·
Nov 07

Stock Track | Royalty Pharma Soars 5.02% on Strong Q3 Results and Raised Guidance

Stock Track
·
Nov 05

Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised

Reuters
·
Nov 05

Royalty Pharma Q3 Adj. EPS $1.17 Beats $1.04 Estimate, Sales $609.000M Miss $739.257M Estimate

Benzinga
·
Nov 05